This Article Full Text Full Text (PDF) Supplementary Material Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Newbold, A. Articles by Johnstone, R. W. Search for Related Content PubMed PubMed Citation Articles by Newbold, A. Articles by Johnstone, R. W.

Research Articles: Therapeutics, Targets, and Development

Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin

¹ Cancer Immunology Program, Peter MacCallum Cancer Centre, Trescowthick Research Laboratories, East Melbourne, Victoria, Australia; ² National Center for Tumor Diseases/German Cancer Research Center, Department of Translational Oncology G100, Heidelberg, Germany; ³ Australian Centre for Blood Diseases, Monash University, Prahran, Melbourne, Victoria, Australia; and ⁴ University of Melbourne, Parkville, Victoria, Australia

Requests for reprints: Ricky W. Johnstone, Cancer Immunology Program, Peter MacCallum Cancer Centre, Trescowthick Research Laboratories, St. Andrews Place, East Melbourne, Victoria 3002, Australia. Phone: 61-3-9656-3727; Fax: 61-3-9656-1411. E-mail: ricky.johnstone{at}petermac.org

Abstract

Histone deacetylase inhibitors (HDACi) are compounds that target the epigenome and cause tumor cell-selective apoptosis. A large number of these agents that have different chemical structures and can target multiple HDACs are being testing in clinical trials and vorinostat is now an approved drug for the treatment of cutaneous T-cell lymphoma. Although these agents are showing promise for the treatment of hematologic malignancies, it is possible that different drugs may have different mechanistic, biological, and therapeutic activities. When comparing an HDACi belonging to the hydroxamic acid class of compounds (vorinostat) with a cyclic tetrapeptide (romidepsin), we showed that these agents regulate the expression of a common set of cellular genes, but certain genes specifically responded to each agent. Using the Eµ-myc mouse model of B-cell lymphoma, we showed previously that overexpression of the prosurvival proteins Bcl-2 and Bcl-X_L inhibited the apoptotic and therapeutic activities of the vorinostat. Herein, we compared and contrasted the apoptotic-inducing activities of the hydroxamic acid oxamflatin with romidepsin. Like vorinostat, oxamflatin was unable to kill lymphomas overexpressing Bcl-2 and Bcl-X_L, indicating that these proteins can generally protect cells against this class of HDACi. In contrast, romidepsin was able to induce apoptosis in lymphomas overexpressing Bcl-2 with delayed kinetics of cell death and could mediate therapeutic responses against these lymphomas. However, romidepsin was inactive when Bcl-X_L was overexpressed. These data provide strong support that HDACi of different chemical classes may have subtle yet potentially important differences in their molecular and biological activities. [Mol Cancer Ther 2008;7(5):1066–79]

Grant support: R.W. Johnstone is a Pfizer Australia research fellow and is supported by National Health and Medical Research Council program grant 251608, Cancer Council Victoria, and Leukemia Foundation of Australia.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

⁵ Supplementary material for this article is available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).

⁶ Unpublished observations.

Received 11/ 4/07; revised 2/ 5/08; accepted 2/21/08.